Andreas Horn interviews experts in the field of deep brain stimulation, noninvasive neuromodulation, functional brain imaging and neuroanatomy. Join us on our quest to interact with the human brain and thank you for your interest in science! Andreas Horn, M.D., Ph.D., directs the institute for network stimulation and is a professor for computational neurology at University Cologne.
Theodore H. Schwartz is a neurosurgeon, author, and the David and Ursel Barnes Endowed Professor of Minimally Invasive Neurosurgery at Weill Cornell Medical Center and New York-Presbyterian Hospital. In this episode of Stimulating Brains, we talk about his book Gray Matters: A Biography of Brain Surgery, a vivid account of what brain surgery really is – personally, technically, historically, psychologically, and morally. We discuss what it actually feels like to be a neurosurgeon: the preparation before a difficult case, the pressure of thousands of micro-decisions, the responsibility for movement, language, memory, and personhood, and the question of when to enter the brain further and when to stop. We also talk about Ted's path from music and astrophysics toward neurosurgery, the culture of surgical training, trauma and gunshot wounds, the history of pioneers such as Cushing, Penfield, Dandy and others, as well as modern brain surgery, pituitary and skull-base surgery, awake mapping, aneurysms, epilepsy, psychosurgery and deep brain stimulation. We even wander toward consciousness, free will, brain-computer interfaces, and the future of less invasive and more computational neurosurgery. At the center of these more philosophical questions lies a deceptively simple question: what can brain surgery teach us about the brain, the self, and the stories we use to understand who we are?
In this episode of Stimulating Brains, I am delighted to welcome back Michael Okun, neurologist, movement-disorders specialist, Adelaide Lackner Distinguished Professor of Neurology at the University of Florida, Director of the Norman Fixel Institute for Neurological Diseases, and National Medical Advisor of the Parkinson's Foundation. Mike was previously on the podcast in episode 25 together with Kelly Foote. This time, we focus on his new book with Ray Dorsey, The Parkinson's Plan: A New Path to Prevention and Treatment. The book argues that Parkinson's disease should not only be treated after diagnosis, but also understood as a public-health challenge that demands prevention, better care models, patient advocacy, and policy. We talk about the PLAN framework: Prevent the disease, Learn why it begins, Amplify the voices of people affected, and Navigate the frontiers of treatment. We discuss environmental risk factors such as pesticides, solvents, dry-cleaning chemicals, air pollution, and paraquat; the idea that "prevention is not a pill, it is policy"; the Parkinson's 25 and the 0-10-100 by 2035 goal. We also talk about what a real care plan should look like for people living with Parkinson's today, including movement-disorder care, rehabilitation, mental health, caregiver support, exercise, speech and swallow therapy, sensors, and access to multidisciplinary teams. Since this is Stimulating Brains, we also return to deep brain stimulation and neuromodulation: where DBS fits into the broader Parkinson's Plan, what circuit-based therapies may still teach us, and how future treatments might connect prevention, biology, devices, genetics, and care.
Karl Friston is one of the most influential neuroscientists of our time and a central figure in the history of human brain mapping. Many listeners will know him for the free energy principle, active inference, dynamic causal modeling, voxel-based morphometry, and many other theoretical contributions. In this episode, we take a different route and go back to the early history of Statistical Parametric Mapping , or SPM : the software and statistical framework that helped turn functional neuroimaging from a local craft into a shared scientific language. We discuss how Karl moved from psychiatry into brain imaging, what the first PET activation experiments felt like, how SPM emerged at the MRC Cyclotron Unit and later the Functional Imaging Laboratory, how the software spread through the neuroimaging community, and how key collaborators helped shape modern PET, fMRI, VBM, DCM, EEG, and MEG analysis. We also talk about mentorship, the culture of the FIL, open software, MNI space, spatial normalization, and what it means for a scientific tool to become infrastructure for an entire field.
In this episode of Stimulating Brains, I speak with Keith R. Mullett, who can uniquely tell a part of the DBS history that is often skipped. We often begin the story of modern DBS in Grenoble around 1987, when Alim-Louis Benabid and colleagues showed that high-frequency VIM stimulation could suppress tremor. Keith reminds us that Medtronic's first DBS system had already been implanted in 1969, not for tremor or Parkinson's disease, but for severe chronic pain. Keith joined Medtronic in May 1972 and spent 37 years there, first in Minneapolis and later at the Bakken Research Center in Maastricht, where he arrived shortly after Frans Gielen. The conversation goes back before the Benabid era, into the period when Medtronic and its physician collaborators built the devices, surgical know-how, clinical relationships, and regulatory experience that later made DBS for movement disorders possible. We discuss Yoshio Hosobuchi and the first pain implants, RF systems with belt-worn transmitters, the transition from cardiac pacing to neurostimulation, the FDA call for data, ITREL, the Bakken Research Center, and the 1992 tremor study: the moment Keith describes as "the rest is history." This episode also connects to our recent conversations with Todd Langevin (episode 46) and Frans Gielen (episode 75). Todd described the internal venturing and business side of DBS after Benabid, while Frans described the engineering, clinical studies, training, imaging, and new indications that followed. Keith, who was Frans' boss, helps us ask what had to exist inside Medtronic before those later teams could build the modern field.
In this episode of Stimulating Brains, I’m honored to speak with Mary Elizabeth Sutherland, a Deputy Editor at Nature whose areas of responsibility include cognitive neuroscience and a broad range of the behavioural and social sciences. If you work with clinical or human neuroscientific data in the field of brain stimulation and choose to submit to Nature, chances are high that Mary Elizabeth will handle your work. Before moving into scientific publishing, she studied at Cornell, completed her PhD at McGill, and did postdoctoral work in Santiago, Chile. Her own research background includes auditory cognitive neuroscience and music cognition. I’m especially looking forward to talking with her about what the job of a Nature editor actually looks like, how editorial decisions are made in a journal with limited space and broad ambition, how human studies are evaluated in that setting, and where scientific publishing may be heading next. The conversation moves through career paths into editorial work, the day-to-day work of a Nature editor, how scientists become professional editors, and the bar for publishing in Nature, with an emphasis on the choices, constraints, and judgments that shape Mary Elizabeth Sutherland's work.
In this episode of Stimulating Brains , we are honored to sit down with György Buzsáki, Professor of Neuroscience at New York University and one of the most influential thinkers in modern neuroscience. Dr. Buzsaki trained as a physician in Hungary, completed his PhD in neuroscience at the Hungarian Academy of Sciences, and went on to postdoctoral training in North America before building a decades-long academic career spanning UC San Diego, Rutgers University, and now NYU. In this conversation, we explore the ideas behind his work on hippocampal oscillations, sharp-wave ripples, and the organization of neural activity across states such as sleep and wakefulness. Dr. Buzsáki reflects on how his early life experiences, technological innovation, and persistent questioning of dominant frameworks shaped a scientific philosophy centered on internal dynamics rather than task-based explanations. Tune in for a rare opportunity to hear one of neuroscience’s most original voices reflect on the past, present, and future of understanding the brain.
In today’s episode of Stimulating Brains, we have the pleasure of speaking with Frans Gielen — a physicist and biomedical engineer who played a foundational role in shaping modern deep brain stimulation. Over more than three decades at Medtronic, Frans worked at the intersection of engineering, neurology, and surgery during the formative years of DBS, when stereotactic imaging protocols, targeting strategies, and surgical workflows were still being defined in real time. He supported and trained teams in more than 2,000 DBS implantations worldwide, helping refine operative techniques and imaging standards long before they became routine. Beyond the operating room, Frans designed and managed several of the pivotal clinical trials that ultimately led to CE marks in Europe and FDA approvals in the United States — including landmark studies in VIM DBS for tremor, STN and GPi DBS for Parkinson’s disease, the first controlled trial of DBS for obsessive–compulsive disorder, and later the MORE trial in epilepsy. In this conversation, we explore the practical, technical, and regulatory work required to transform DBS from a promising idea into a reliable, evidence-based therapy — and reflect on what it took to build the foundations that the field stands on today.
In this episode of Stimulating Brains , we sit down with Dr. Ludwig Zrinzo, Professor of Functional Neurosurgery at University College London and Head of the Functional Neurosurgery Unit at Queen Square. Drawing on decades of experience at the forefront of deep brain stimulation, Dr. Zrinzo reflects on the evolution of DBS from awake procedures to image-guided surgery under general anesthesia, emphasizing why precision, verification, and closing the loop are essential for improving patient outcomes. We discuss how his experience shaped a rigorous, data-driven approach to targeting, why imaging quality remains a very critical factor in DBS accuracy, and how systematic post-operative verification transformed clinical practice. Beyond technique, Dr. Zrinzo shares deeply insightful perspectives on patient selection, mentorship, leadership, and the responsibility of building sustainable teams in academic neurosurgery. The conversation also ventures into neuropsychiatric DBS, including OCD, where we examine how stimulation in different targets may have differential effects on behavior, illuminating the brain’s underlying circuitry. Finally, we look into the future of adaptive and closed-loop stimulation, emerging electrode technologies, and the future balance between innovation, scalability, and patient-centered care. Tune in for a thoughtful and wide-ranging conversation on precision, evidence, and humanity in brain stimulation — and on how functional neurosurgery continues to teach us how the brain truly works.
In this episode of Stimulating Brains , we sit down with Dr. Eyal Zadicario, Chief Operating Officer at Insightec, to explore the remarkable evolution of focused ultrasound – from its experimental origins to its transformative role in functional neurosurgery today. Dr. Zadicario shares insights from over two decades at the forefront of innovation, reflecting on the challenges of translating breakthroughs from academia to industry, designing clinician-friendly systems that prioritize the patient experience, and overcoming skepticism toward disruptive technologies. Together, we revisit key milestones – from the first MRgFUS based thalamotomy in 2008 and early applications in breast cancer, to the expanding frontiers of neuromodulation. Looking ahead, we discuss the exciting possibilities of blood brain barrier opening, the acoustic neurosurgical suite, and even brain mapping through focused sound. Tune in for a fascinating conversation on how precision acoustics are reshaping the landscape of brain therapy and beyond.
Today, we had the privilege of speaking with Dr. John Rolston, a leading voice at the intersection of neurosurgery, epilepsy, and brain stimulation. Dr. Rolston is an Associate Professor of Neurosurgery at Harvard Medical School and the Director of Epilepsy Surgery at Brigham and Women’s Hospital. His pioneering work bridges clinical neurosurgery and computational neuroscience, focusing on how electrical stimulation can modulate dysfunctional brain networks to treat epilepsy, movement disorders, and disorders of consciousness. In this episode, we explored the complexities of neuromodulation—what makes stimulation effective, why patient-specific targeting matters, and how brain states influence therapeutic outcomes. Dr. Rolston also shared his lab’s work on traveling waves in the brain and how these insights are transforming seizure localization and surgical decision-making. From closed-loop stimulation to stem cell therapy for Parkinson’s disease, Dr. Rolston walks us through the evolving landscape of functional neurosurgery and its future.
Today we had the privilege of speaking with a true pioneer in the field of neuropsychiatry and brain stimulation— Dr. Harold Sackeim. Dr. Sackeim is perhaps best known for his extensive research on electroconvulsive therapy (ECT), but his contributions span a wide range of topics from treatment-resistant depression to the placebo effect in neurostimulation. As a founding figure in modern ECT research, he has played a central role in shaping both the science and the clinical practice of brain stimulation therapies. In this episode, we explored the history and future of ECT, the controversies surrounding it, and Dr. Sackeim’s insights on the direction of neuromodulation. He explains how ECT has long been the most effective treatment for severe, treatment-resistant depression. While once overlooked in favor of medication, we now know that both the placement and intensity of stimulation are key—challenging the old belief that seizures alone drive its effects.
In this episode, we journey through the remarkable career of Dr. Rees Cosgrove—a trailblazer in functional neurosurgery, Director of Epilepsy and Functional Neurosurgery at Brigham and Women’s Hospital, and Professor of Neurosurgery at Harvard Medical School. Dr. Cosgrove reflects on his formative years training in the very halls that were roamed by legends such as Wilder Penfield at the Montreal Neurological Institute, and takes us through pivotal chapters of his career leading programs at Massachusetts General Hospital, Brown University, and now the Brigham. With a repertoire that spans from the golden era of ablative neurosurgery to modern deep brain stimulation and MR-guided focused ultrasound—where he has performed over 600 sonications—Dr. Cosgrove provides a unique perspective on how the field has transformed over the past several decades. Throughout the conversation, we delve into the history and resurgence of surgical lesions for psychiatric and neurological conditions, the nuances of neuromodulation technologies, and the evolution of imaging that now defines precision in brain surgery. Dr. Cosgrove also shares his views on mentorship, the transmission of surgical wisdom, and how we can preserve the disappearing art of lesioning in an age increasingly dominated by stimulation. Whether you're a neurosurgeon, neuroscientist, or simply curious about how we interface with the brain to treat disease, this episode is a rare and insightful look into the mind of one of the field’s most experienced and thoughtful pioneers.
In this episode we will dive deep into the minds of leading researchers and clinicians in the field of neuromodulation. Today, we are thrilled to have Dr. Terry Sanger with us. Dr. Sanger is a renowned pediatric neurologist, engineer, and Chief Scientific Officer at CHOC, where he focuses on improving the lives of children with movement disorders—especially dystonia. He’s well known for combining deep computational approaches with cutting-edge neuromodulation techniques. In this episode, we’ll uncover how his background in engineering, neuroscience, and clinical practice converges to shape new possibilities for treating complex movement disorders in children. From pioneering multi-electrode deep brain stimulation for pediatric dystonia to his latest forays in closed-loop stimulation research, Dr. Sanger is truly expanding the boundaries of what’s possible in pediatric care.
In this episode, we have the privilege of speaking with Dr. Todd Herrington, a leading neurologist and director of the Deep Brain Stimulation (DBS) program at Massachusetts General Hospital. Dr. Herrington specializes in movement disorders such as Parkinson’s disease, tremor, and dystonia, and his research focuses on the motor, cognitive, and psychiatric effects of DBS, leveraging intraoperative and noninvasive neurophysiology and neuroimaging to advance neuromodulation therapies. Today, we’ll explore his key role in the ADAPT PD trial, a groundbreaking multicenter study evaluating the safety and efficacy of adaptive DBS for Parkinson’s disease. This trial, led by Dr. Helen Brontë-Stewart at Stanford, introduced a neurostimulator capable of sensing local field potentials and dynamically adjusting stimulation in real time based on a patient’s brain activity. We’ll discuss how this technology represents a shift toward personalized DBS therapy and what it means for the future of neuromodulation. In the second part of our conversation, we’ll delve into broader topics, including the mechanism of action of DBS, novel neuromodulation approaches, and the potential role of stem cell therapy in movement disorders. Dr. Herrington shares his expert insights on how these advancements shape both our scientific understanding and the clinical application of DBS. From improving motor and non-motor symptoms in Parkinson’s disease to pioneering adaptive neurostimulation, his work is at the forefront of innovation in the field.
In this episode, we’re joined by Dr. Jonathan Downar, a psychiatrist and neuroscientist based in Toronto, renowned for his pioneering research in transcranial magnetic stimulation (TMS) for depression. You may recognize him from his landmark work on the Three-D Trial, which helped establish intermittent theta-burst stimulation (iTBS) as a rapid and effective alternative to standard repetitive TMS. Recently, Jonathan has been pushing the boundaries of TMS with accelerated treatment protocols, including the One-D Study, which tested the feasibility of delivering an entire TMS course in a single day. In our conversation, we explore his scientific journey, the future of brain stimulation, and his bold approach to innovation—what he calls “TMS in SpaceX mode.” We also discuss the vision for achieving a billion depression patient remissions in our lifetime. Tune in for an inspiring and insightful discussion with one of the leaders in neuromodulation research.
In this episode, we have a privilege to talk with Dr. Roxanne Lofredi, a prominent researcher investigating movement disorders and deep brain stimulation (DBS). Dr. Lofredi is based at Charité – Universitätsmedizin Berlin and is widely recognized for her groundbreaking contributions to understanding how basal ganglia networks drive motor symptoms in conditions such as dystonia and Parkinson’s disease. Today, we’ll explore two fascinating studies led by Dr. Lofredi. The first focuses on how subthalamic nucleus stimulation impairs stopping of ongoing movements in Parkinson’s disease. This work, published in Brain, was inspired by a foundational basic science study from Aron and Poldrack (2006), which first implicated the subthalamic nucleus as a critical node for motor inhibition within the hyperdirect pathway of the basal ganglia. We’ll discuss how these findings translated to her DBS study and how they may impact DBS therapy. The second part of our conversation will cover her recent publication in Nature Communications , where Dr. Lofredi and her team demonstrate a clear link between striato-pallidal oscillatory connectivity and symptom severity in dystonia. This work highlights the pathophysiological role of the direct pathway within the basal ganglia and opens up new possibilities for targeted therapeutic approaches. In conclusion, Dr. Lofredi shares key insights from her research, bridging the gap between basic neuroscience and clinical application. From understanding motor inhibition in Parkinson's disease to exploring striato-pallidal connectivity in dystonia, her work advances our knowledge and paves the way for more effective DBS therapies.
In this episode of Stimulating Brains , we're thrilled to have Jim McNasby join us. Jim is a deep brain stimulation (DBS) patient and the Chief Counsel at the Michael J. Fox Foundation. Jim has an inspiring story, not just as a DBS patient but also as a legal professional working at the forefront of Parkinson’s research advocacy. We’ll dive into his personal experience with DBS—how it has shaped his life since his diagnosis in 2000 and his surgery in 2019—and explore his crucial role at the Michael J. Fox Foundation, where he helps drive forward their mission to find a cure for Parkinson’s disease. I had the pleasure of hearing Jim speak at the Neuromodec Conference, where he shared a powerful story of how DBS transformed his life, even showing a video that vividly captured its positive effects. We’ll talk about that, his DBS wishlist, and the work he’s doing to advocate for patients and drive research. In this episode, we explore his personal experiences, the impact of DBS, and his role in advancing Parkinson's research and advocacy at the foundation. Jim also reflects on the transformative moment when his DBS was first activated and discusses his vision for the future of patient care and innovation in the field.
Today, we have the pleasure of speaking with Dr. Bálint Várkuti, a distinguished expert in the field of neuromodulation. Dr. Várkuti is the founder and CEO of CereGate , a pioneering company developing brain-computer interface technologies—referred to as computer-brain interface technologies—that aim to enhance neuromodulation therapies. Before founding CereGate , Dr. Várkuti made significant contributions to image-guided DBS programming solutions at Brainlab . With over a decade of experience in neurotechnology and the medical device industry, his work focuses on designing innovative interfaces between technology and the human brain to improve patient outcomes. For those familiar with DBS, you’ll understand the nuances here: when stimulation of the super-dynamic nucleus in DBS is set too high, patients often experience a tingling or irritating sensation due to overstimulation of sensory fibers. Typically, this side effect is avoided. However, Dr. Várkuti had a groundbreaking insight: This sensation represented a channel of information with the brain – and one could make use of it! In a nutshell, CereGate leverages these overlooked pathways, using them in a patterned and complex way to transmit information that the brain can decode. This approach opens up new possibilities for interfacing with the brain, which we find truly fascinating: This concept that CereGate is exploring might just be the start of a much larger field of innovation.
In this episode, we have the pleasure of hosting Mark McAuley, a deep brain stimulation (DBS) patient and the CEO of Astronomy Australia Limited, and Dr. Susan Boehnke, an Associate Professor at Queen’s University in Canada and director of the Neurotech Microcredential Program and the Neurotech Discovery Lab. Together, they've been part of remarkable efforts that not only focus on the practical and ethical aspects of neurotechnology but also engage students in real-time research. Mark brings over thirty years of experience in research and development, with a remarkable track record of securing $300 million in Australian Government grants for major research infrastructure projects. Holding degrees in astrophysics, ancient history, and an MBA—where he was awarded the Vice-Chancellor’s medal as the university's highest-achieving postgraduate student—Mark was diagnosed with Parkinson’s disease in 2010 and received a DBS implant in 2020. Post-surgery, he's been a passionate advocate for better patient care and improved DBS programming to enhance clinical outcomes. Dr. Susan Boehnke completed her PhD in Neuroscience at Dalhousie University and has an extensive background in auditory neuroscience and primate neurophysiology. She led the creation of one of the first non-human primate models of Alzheimer’s disease and established Canada's first non-human primate biobank. In response to the explosion of interest in neurotechnology, she's now pioneering a micro-credential program in neurotech and exploring the ethical issues surrounding it. She's also leading the Training Committee for Connected Minds, a significant research initiative between York and Queen’s Universities. At the recent Neuromodec conference in New York, Mark and Susan presented their work, which emphasizes patient inclusion in research—a theme Dr. Boehnke passionately advocates for—and provides transformative learning experiences for students. Today, we'll dive into their journeys, the science behind their projects, and explore potential insights into the future of patient-led research and education in neurotechnology.
In today’s episode, we dive deep into two groundbreaking studies led by Daniela and Clément. We explore their 2022 Nature Communications paper on using cerebellar stimulation to alleviate levodopa-induced dyskinesias in Parkinson’s disease and discuss their 2023 paper uncovering the cerebellum’s role in regulating fear extinction through its connections with the thalamo-prefrontal cortex pathway. Along the way, we discuss how these discoveries may open up exciting new possibilities for treating both motor and emotional disorders. Tune in for an insightful conversation packed with cutting-edge science and exciting future perspectives!
